Janux Therapeutics Inc (JANX) - News Archive

Janux Therapeutics Closes $402.5 Million Public Offering Amid Revenue Challenges In a compelling development for the biopharmaceutical sector, Janux Therapeutics, Inc. (Nasdaq: JANX), has successfully closed its underwr...

Janux Therapeutics, Inc. (Nasdaq: JANX), a pioneering clinical-stage biopharmaceutical company, has recently announced a substantial public offering valued at $350 million. The offering, aimed at accelerating its innova...

Janux Therapeutics Inc, a prominent player in the biotechnology sector, has faced a challenging year in terms of its stock performance. Its shares have been trailing behind the overall market, raising concerns among inv...

Decoding the Investment Puzzle: Evaluating Janux Therapeutics Inc against Protagonist Therapeutics Inc and Qiagen NVIf you re contemplating an investment in the biotech industry, specifically in Janux Therapeutics Inc o...